近日获悉,天津健诺康生物科技有限公司(Genocure)宣布与全球领先的合同研发生产组织(CDMO)凯莱英(Asymchem)达成合作,成功实现了全球首个基因重组PDRN(rPDRN,recombinant PDRN)的GMP级规模化生产。Genocure × Asymchem联手,以无法复制的技术壁垒,彻底改写核酸疗法规则。“重组型PDRN,也许可以模仿。但要复制Genocure的rPDRN?...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.